Pieris Pharmaceuticals Interest Expense 2011-2026 | PIRS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Pieris Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
727 K	-131 K	712 K	1.3 M	2.4 M	-3.66 M	-26 K	1.8 M	-2.1 M	120 K	10.9 K	2.65 M	494 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.65 M	-3.66 M	332 K

Quarterly Interest Expense Pieris Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
34 K	561 K	224 K	-	-20 K	64 K	171 K	-	506 K	-161 K	-57 K	-	723 K	676 K	229 K	-	678 K	464 K	884 K	-	-1.34 M	-424 K	-60 K	-	-55 K	23 K	-171 K	-	1.15 M	1.23 M	-903 K	-	-1.73 M	-1.38 M	12 K	-	-18.2 K	-87.8 K	220 K	-	-1.93 K	53	4.17 K	-	148	114 K	109 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.23 M	-1.73 M	46.3 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Ascendis Pharma A/S ASND	80.6 M	$ 229.25	0.44 %	$ 5 B	Danmark
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
AbbVie ABBV	2.89 B	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.52	0.28 %	$ 1.05 B	Canada
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	72.4 M	$ 3.33	-2.06 %	$ 99 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Adaptive Biotechnologies Corporation ADPT	11.8 M	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	-190 K	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	14.2 M	$ 91.18	1.97 %	$ 27.2 B	Germany
ANI Pharmaceuticals ANIP	-4.03 M	$ 74.21	-2.3 %	$ 1.43 B	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 8.03	2.29 %	$ 220 M	Israel
Autolus Therapeutics plc AUTL	36.7 M	$ 1.41	2.17 %	$ 375 M	Britain
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aytu BioScience AYTU	-512 K	$ 2.68	1.52 %	$ 16.8 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
BioCryst Pharmaceuticals BCRX	59.3 M	$ 9.02	-3.84 %	$ 1.86 B	USA
Axcella Health AXLA	3.02 M	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	286 M	$ 412.81	-2.54 %	$ 31.3 B	USA
Alnylam Pharmaceuticals ALNY	5.2 M	$ 318.85	-3.01 %	$ 41.8 B	USA